retatrutide type 2 diabetes trial results 2024 ESC 2024: improves lipid and cardiovascular risk profile in Phase II retatrutide type 2 diabetes phase

Although Tesomet received an Orphan Drug designation from the FDA in 2021, its development was discontinued in 2022 due to funding constraints

Information extracted from eligible articles that were tracked by the reviewers included data such as article title, authors, journal name, year of publication, article type, data source, clinical setting, patient demographics, prior patient pulmonary or gastric history, patient medications noted, system-based comorbidities, extent of adverse event, diagnostics used, study methods, study of patient outcomes, limitations, and conclusions

When not looking at stocks, Yash loves a game of table tennis or chess.

And GLP-1based therapies may become one of the most important disease-modifying strategies in this new era of integrated metabolic medicine

Vitamin B12 is naturally present almost exclusively in animal-derived foods, making vegans and strict vegetarians particularly vulnerable unless they consume fortified foods or supplements